Technical Analysis for LPCN - Lipocine Inc.

Grade Last Price % Change Price Change
grade D 0.45 -4.26% -0.02
LPCN closed down 4.26 percent on Monday, January 27, 2020, on 47 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Down
Historical LPCN trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Outside Day Range Expansion -4.26%
Wide Bands Range Expansion -4.26%
Down 3 Days in a Row Weakness -4.26%
Calm After Storm Range Contraction -11.76%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Lipocine Inc., a specialty pharmaceutical company, is engaged in the development of pharmaceutical products in the areas of men's and women's health. The company offers a portfolio of proprietary product candidates that are used to produce pharmacokinetic characteristics; facilitate lower dosing requirements and bypass first-pass metabolism; reduce side effects; and eliminate gastrointestinal interactions that limit bioavailability. Its product candidates for men's health include LPCN 1021, an oral product candidate, which is in Phase III clinical trials; and LPCN 1111, an oral product candidate that is in Phase I/II clinical trials for the treatment of testosterone replacement therapy. The company's product candidates for women's health comprise LPCN 1107, which is in Phase I/II clinical trials for the prevention of preterm birth. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah.
Chemistry Health Pharmaceutical Pharmaceutical Products Clinical Trial Alcohols Design Of Experiments Clinical Research Bypass Ketones Androstanes Testosterone Testosterone Replacement Therapy

Is LPCN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Date Title
Jan 14 TUESDAY DEADLINE REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Lipocine Inc. and Encourages Investors with Losses to Contact the Firm
Jan 14 DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Lipocine Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Jan 14 LPCN FINAL DEADLINE TODAY: Rosen, a Leading Law Firm, Reminds Lipocine Inc. Investors of Important January 14th Deadline in Securities Class Action – LPCN
Jan 14 TUESDAY DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Lipocine, Inc. and Encourages Investors to Contact the Firm
Jan 13 LPCN FINAL DEADLING: ROSEN, A TOP FIRM, Reminds Lipocine Inc. Investors of Important January 14 Deadline in Securities Class Action - LPCN
Jan 13 FILING DEADLINE TOMORROW: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Lipocine Inc.
Jan 13 FINAL DEADLINE ALERT - Lipocine Inc. (LPCN) - Bronstein, Gewirtz & Grossman, LLC Reminds Investors With Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: January 14, 2020
Jan 13 TUESDAY DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against Lipocine Inc. and Encourages Investors with Losses to Contact the Firm
Jan 9 5-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Lipocine Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Jan 9 DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Lipocine, Inc. and Encourages Investors to Contact the Firm
See more LPCN news...

Indicators

Indicator Value
52 Week High 3.45
52 Week Low 0.32
Average Volume 1,342,972
200-Day Moving Average 1.76
50-Day Moving Average 0.42
20-Day Moving Average 0.45
10-Day Moving Average 0.49
Average True Range 0.06
ADX 32.42
+DI 29.47
-DI 21.93
Chandelier Exit (Long, 3 ATRs ) 0.44
Chandelier Exit (Short, 3 ATRs ) 0.51
Upper Bollinger Band 0.57
Lower Bollinger Band 0.33
Percent B (%b) 0.5
BandWidth 52.20
MACD Line -0.02
MACD Signal Line -0.04
MACD Histogram 0.0208
Fundamentals Value
Market Cap 9.26 Million
Num Shares 20.6 Million
EPS -0.93
Price-to-Earnings (P/E) Ratio -0.48
Price-to-Sales 0.00
Price-to-Book 2.86
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.50
Resistance 3 (R3) 0.50 0.48 0.49
Resistance 2 (R2) 0.48 0.47 0.48 0.48
Resistance 1 (R1) 0.47 0.46 0.46 0.47 0.48
Pivot Point 0.45 0.45 0.45 0.45 0.45
Support 1 (S1) 0.44 0.44 0.43 0.44 0.42
Support 2 (S2) 0.42 0.43 0.42 0.42
Support 3 (S3) 0.41 0.42 0.41
Support 4 (S4) 0.41